Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Justin S. Waters"'
Autor:
John Bridgewater, Stephen Falk, Kinnari Patel, Alan Anthoney, Harpreet Wasan, W David J Ryder, Safia Barber, Juan W. Valle, Daniel H. Palmer, Yuk Ting Ma, Roopinder Gillmore, Arvind Arora, Jonathan Wadsley, John Ramage, Angela Lamarca, Claire Hobbs, Timothy Iveson, Justin S. Waters, Linda Davies, Paul Ross, Anthony Maraveyas
Publikováno v:
The Lancet Oncology. 22:e288-e289
Autor:
Daniel Catovsky, Matthew C.H. Ng, A C Wotherspoon, David Cunningham, Mark A. Hill, Alan Horwich, Ian Chau, A. R. Norman, Justin S. Waters
Publikováno v:
British Journal of Cancer
There is currently no standard salvage chemotherapy regimen in relapsed and refractory lymphoma. Gemcitabine is a novel nucleoside analogue, which acts synergistically with cisplatin both in vitro and in clinical studies. We evaluated the combination
Autor:
Roger A'Hern, Tim Eisen, M. G. James, S Hackett, Justin S. Waters, Martin Gore, C Moss, Lynda Pyle
Publikováno v:
British Journal of Cancer
We report a single institution phase II study of gemcitabine 1200 mg m(-2) i.v. on days 1 and 8 and capecitabine 1300 mg m(-2) twice daily on days 1-14 of each 3-week cycle in patients with metastatic renal carcinoma. Patients had a WHO performance s
Autor:
M.E. Hill, Justin S. Waters, A. R. Norman, Gina Brown, Jacqui Oates, David Cunningham, L. Assersohn, C. Ward
Publikováno v:
Annals of Oncology. 15:64-69
Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma Background: The purpose of this study was to assess the efficacy and toxicity of irinotecan and 5-fl
Publikováno v:
British Journal of Cancer
The purpose of this study was to evaluate the activity and safety of oxaliplatin and protracted venous infusion of 5-fluorouracil (PVI 5-FU) in patients with advanced or relapsed 5-FU pretreated colorectal cancer. 38 patients with advanced or metasta
Autor:
Andrew Webb, Justin S. Waters, Florence I. Raynaud, F Di Stefano, Paul A. Clarke, David Cunningham, Finbarr E. Cotter
Publikováno v:
Europe PubMed Central
PURPOSE: To evaluate the pharmacokinetics and toxicity of an antisense oligonucleotide targeting bcl-2 in patients with non-Hodgkin’s lymphoma (NHL) and to determine efficacy using clinical and biologic end points. PATIENTS AND METHODS: Twenty-one
Autor:
Andrea Formentini, M. Büchler, D. Birk, J.P. Neoptolemos, Justin S. Waters, C. Bassi, Frank Gansauge, Dan Danielsson, Argenis Castro, A. Gumbs, Francesco Gambilonghi, Fermín Mearin, D.J. Kerr, Margaret D. Finch, Ian O. Ellis, M.W. Büchler, C. Dervenis, Wojtek Karlik, K. Link, John P. Neoptolemos, Paula Ghaneh, Bengt Jeppsson, J. Jeekel, L. Fernandez-Cruz, Sergio Pedrazzoli, Hans Günther Beger, Maria Weichetek, James Carmichael, Giacomo Laffi, Roger Mountford, Karl-Heinrich Link, J. Kleeff, Sabrina Vecchiarino, Truls Hauge, James D. Evans, Hans G. Beger, P. Pederzoli, Chiara Lazzeri, Anna-Lena Grahm, David Cunningham, Anthony Kawesha, Nicholas R. Lemoine, José M. Gil-Vernet, Juan-R. Malagelada, Jesper Persson, Nathan Howes, H. Friess, R. A. Popescu, Stanislaw Garwacki, Claudio Bassi, F. Laçaine, Massimo Falconi, Peeyush Sharma, Giorgio La Villa, Paul Ross, Paolo Pederzoli, E. Papachristov, Michael Raraty, Robert Sutton, Åke Andrén-Sandberg, Paolo Gentilini, H. Beger, Franco Franchi, P. Hermanek, G. Fortnagel
Publikováno v:
Digestion. 58:I-V
Autor:
Ian Chau, Mark A. Hill, Gary Middleton, P J Ross, Jacqui Oates, C. Topham, R Katopodis, A. R. Norman, Justin S. Waters, G. Stewart, David Cunningham
Publikováno v:
British Journal of Cancer
Elderly patients are recommended to have a reduced starting dose (300 mg m(-2) once every 3 weeks) of irinotecan monotherapy. The aims of this analysis are to compare toxicity and survival according to age, performance status (PS), gender and prior r
Autor:
J H Scarffe, Tamas Hickish, M. Nicolson, Sheela Rao, A Hill, Andrew Webb, Peter Harper, Johnathan Joffe, Justin S. Waters, M Leahy, Janine Mansi, M Mackean, A. R. Norman, David Cunningham, Jacqui Oates
Publikováno v:
British Journal of Cancer
We report the final results of a prospectively randomized study that compared the combination of epirubicin, cisplatin and protracted venous infusion fluorouracil (5-FU) (ECF regimen) with the standard combination of 5-FU, doxorubicin and methotrexat
Publikováno v:
Europe PubMed Central
A number of new cytotoxic agents are currently being assessed for the treatment of gastro-intestinal cancers. Colorectal cancer has been successfully treated with several direct thymidylate synthase inhibitors, oral 5-fluorouracil analogues, irinotec